XML 41 R25.htm IDEA: XBRL DOCUMENT
v3.23.1

Share-based Payments | 12 Months Ended
--- | ---
Mar. 31, 2023
Share-based Payments [Abstract] |
Share-based Payments | 18. Share-based Payments In September 2022, the Company’s shareholders approved the 2022 Incentive Award Plan (the “2022 Plan”), which replaced the 2010 Incentive Award Plan and the 2014 Non-Employee Director Incentive Award Plan. Under the 2022 Plan, a total of 924,200 shares of the Company’s common stock were reserved for grants to its employees, non-employee directors, and consultants. At March 31, 2023, there were 52,768 shares of restricted stock units outstanding and 871,432 shares of common stock were available for grant under this plan. At March 31, 2023 and 2022, 10,417 and 82,324 of restricted stock units, respectively, were outstanding under the 2014 Non-Employee Director Incentive Award Plan. No shares of common stock remain available for grant under this plan. At March 31, 2023 and 2022, respectively, there was (i) 266,169 and 216,739 shares of restricted stock units were outstanding, (ii) options to purchase 1,226,745 and 1,674,499 shares of common stock were outstanding, (iii) 100,000 and 100,000 restricted shares were outstanding, and (iv) 192,696 and 84,593 shares of performance stock units were outstanding under the 2010 Incentive Award Plan. No shares of common stock remain available for grant under this plan. In addition, at March 31, 2023 and 2022, options to purchase 6,000 and 21,000 shares of common stock, respectively, were outstanding under the 2004 Non-Employee Director Stock Option Plan. No options remain available for grant under this plan. Stock Options The Company did not grant any stock options during the year ended March 31, 2023 and 2022. The following summarizes the Black-Scholes option-pricing model assumptions used to derive the weighted average fair value of the stock options granted during the year ended March 31, 2021.
|  | Years Ended March 31,
|  | 2021
Weighted average risk free interest rate |  |  | 0.44 | %
Weighted average expected holding period (years) |  |  | 5.96 |
Weighted average expected volatility |  |  | 44.90 | %
Weighted average expected dividend yield |  |  | - |
Weighted average fair value of options granted |  | $ | 6.43 |
The following is a summary of stock option transactions:
|  | Number of |  |  | Weighted Average |
|  | Shares |  |  | Exercise Price |
Outstanding at March 31, 2022 |  |  | 1,695,499 |  |  | $ | 17.53 |
Granted |  |  | - |  |  | $ | - |
Exercised |  |  | (326,469 | ) |  | $ | 6.75 |
Forfeited/Cancelled |  |  | (123,932 | ) |  | $ | 19.45 |
Expired |  |  | (12,353 | ) |  | $ | 15.91 |
Outstanding at March 31, 2023 |  |  | 1,232,745 |  |  | $ | 20.20 |
At March 31, 2023, options to purchase 96,495 shares of common stock were unvested at the weighted average exercise price of $15.16. Based on the market value of the Company’s common stock at March 31, 2023, 2022, and 2021, the pre-tax intrinsic value of options exercised was $2,427,000, $245,000, and $546,000, respectively. The total fair value of stock options vested during the years ended March 31, 2023, 2022, and 2021 was $1,140,000, $2,174,000, and $2,184,000, respectively. The following summarizes information about the options outstanding at March 31, 2023:
|  |  | Options Outstanding |  | Options Exercisable
|  |  |  |  |  |  |  |  | Weighted |  |  |  |  |  |  |  |  |  | Weighted |  |
|  |  |  |  |  | Weighted |  |  | Average |  |  |  |  |  |  | Weighted |  |  | Average |  |
|  |  |  |  |  | Average |  |  | Remaining |  | Aggregate |  |  |  |  | Average |  |  | Remaining |  | Aggregate
Range of |  |  |  |  |  | Exercise |  |  | Life |  | Intrinsic |  |  |  |  | Exercise |  |  | Life |  | Intrinsic
Exercise price |  |  | Shares |  |  | Price |  |  | In Years |  | Value |  | Shares |  |  | Price |  |  | In Years |  | Value
$ | 6.48 to $18.20 |  |  |  | 405,418 |  |  | $ | 13.33 |  |  |  | 4.83 |  |  |  |  | 308,923 |  |  | $ | 12.76 |  |  |  | 4.08 |  |
$ | 18.21 to $22.83 |  |  |  | 438,637 |  |  |  | 19.58 |  |  |  | 5.78 |  |  |  |  | 438,637 |  |  |  | 19.58 |  |  |  | 5.78 |  |
$ | 22.84 to $28.04 |  |  |  | 178,566 |  |  |  | 26.27 |  |  |  | 3.50 |  |  |  |  | 178,566 |  |  |  | 26.27 |  |  |  | 3.50 |  |
$ | 28.05 to $31.13 |  |  |  | 210,124 |  |  |  | 29.60 |  |  |  | 2.95 |  |  |  |  | 210,124 |  |  |  | 29.60 |  |  |  | 2.95 |  |
|  |  |  |  | 1,232,745 |  |  | $ | 20.20 |  |  |  | 4.66 | $ | - |  |  | 1,136,250 |  |  | $ | 20.63 |  |  |  | 4.44 | $ | -
The aggregate intrinsic values in the above table represent the pre-tax value of all in-the-money options if all such options had been exercised on March 31, 2023 based on the Company’s closing stock price of $7.44 as of that date. At March 31, 2023, there was $132,000 of total unrecognized compensation expense from stock-based compensation granted under the plans, which is related to non-vested shares. The compensation expense is expected to be recognized over a weighted average vesting period of three months. Restricted Stock Units and Restricted Stock (collectively “RSUs”) During the years ended March 31, 2023 and 2022, the Company granted (i) performance-based restricted stock awards which had a threshold performance level of 33,333 shares, a target performance level of 66,667 shares, and a maximum performance level of 100,000 shares at the grant date for both periods and (ii) 229,121 and 163,703 of time-based vesting restricted stock units, respectively. The estimated grant date fair value of the RSUs $4,430,000, $5,775,000, and $4,150,000, for the years ended March 31, 2023, 2022, and 2021, respectively, which was based on the closing market price on the date of grant. The fair value related to these awards is recognized as compensation expense over the vesting period. These awards generally vest in three equal installments beginning each anniversary from the grant date, subject to continued employment. Upon vesting, these awards may be net share settled to cover the required withholding tax with the remaining amount converted into an equivalent number of shares of common stock. Total shares withheld during the years ended March 31, 2023 and 2022 were 74,854 and 84,762, respectively, based on the value of these awards as determined by the Company’s closing stock price on the vesting date. The following is a summary of non-vested RSUs:
|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value |
Outstanding at March 31, 2022 |  |  | 399,063 |  |  | $ | 19.98 |
Granted |  |  | 329,121 |  |  | $ | 13.46 |
Vested |  |  | (228,519 | ) |  | $ | 20.08 |
Forfeited/Cancelled |  |  | (70,311 | ) |  | $ | 19.15 |
Outstanding at March 31, 2023 |  |  | 429,354 |  |  | $ | 15.07 |
As of March 31, 2023, there was $3,289,000 of unrecognized compensation expense related to these awards, which will be recognized over the remaining vesting period of approximately 1.5 years. The Company’s unrecognized compensation expense includes restricted stock awards at the target performance level as deemed probable at each quarter-end. Performance Stock Units (“PSUs”) During the years ended March 31, 2023 and 2022, the Company granted 126,028 and 84,593 of performance-based PSUs (at target performance levels), respectively, to its executives, which typically cliff vest after three-years subject to continued employment. These awards are contingent and granted separately for each of the following metrics: adjusted EBITDA, net sales, and relative total shareholder return (“TSR”). Compensation cost is determined at the grant date and recognized on a straight-line basis over the requisite service period to the extent the conditions are deemed probable. The number of shares earned at the end of the three-year period will vary, based only on actual performance, from 0% to 150% of the target number of PSUs granted. PSUs are not considered issued or outstanding ordinary shares of the Company. Adjusted EBITDA and net sales are considered performance conditions. The Company will reassess the probability of achieving each performance condition separately each reporting period. TSR is considered a market condition because it measures the Company’s return against the performance of the Russell 3000, excluding companies classified as financials and real estate, over a given period of time. Compensation cost related to the TSR award will not be adjusted even if the market condition is not met. The Company calculated the fair value of the PSUs for each component individually. The fair value of PSUs subject to performance conditions is equal to the closing stock price on the grant date. The fair value of PSUs subject to the market condition is determined using the Monte Carlo valuation model. The following table summarizes the assumptions used in determining the fair value of the TSR awards:
|  | Year Ended March 31, |
|  | 2023 |  |  | 2022 |
Risk free interest rate |  |  | 3.35 | % |  |  | 0.47 | %
Expected life in years |  |  | 3 |  |  |  | 3 |
Expected volatility of MPA common stock |  |  | 51.30 | % |  |  | 53.70 | %
Expected average volatility of peer companies |  |  | 62.70 | % |  |  | 59.30 | %
Average correlation coefficient of peer companies |  |  | 27.50 | % |  |  | 26.70 |
Expected dividend yield |  |  | - |  |  |  | - |
Grant date fair value |  | $ | 16.02 |  |  | $ | 26.89 |
The following is a summary of non-vested PSUs:
|  | Number of Shares |  |  | Weighted Average Grant Date Fair Value |
Outstanding at March 31, 2022 |  |  | 84,593 |  |  | $ | 23.19 |
Granted |  |  | 126,028 |  |  | $ | 14.00 |
Vested |  |  | - |  |  | $ | - |
Forfeited/Cancelled |  |  | (17,925 | ) |  | $ | 19.95 |
Outstanding at March 31, 2023 |  |  | 192,696 |  |  | $ | 17.48 |
At March 31, 2023, there was $1,926,000 of unrecognized compensation expense related to these awards, which will be recognized over the weighted average remaining vesting period of approximately 1.9 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration